The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, Guizhou, 563000, China.
Dali University, No.2 Hongsheng Road, Dali Town, Dali City, 671003, Yunnan Province, China.
J Transl Med. 2024 Sep 2;22(1):814. doi: 10.1186/s12967-024-05631-8.
Breast cancer, with its high morbidity and mortality rates, is a significant global health burden. Traditional treatments-surgery, chemotherapy, and radiotherapy-are widely used but come with drawbacks such as recurrence, metastasis, and significant side effects, including damage to healthy tissues. To address these limitations, new therapeutic strategies are being developed. Peroxidases (POD) can catalyze excess HO in the tumor microenvironment to generate reactive oxygen species (ROS), which induce cancer cell apoptosis by disrupting redox homeostasis and modulating apoptosis-related proteins. However, natural enzymes face challenges like poor stability, high cost, and sensitivity to environmental conditions, limiting their application in breast cancer treatment. Nanozymes, nanomaterials with enzyme-like activity, offer a promising alternative by overcoming these limitations.
In this study, we successfully prepared Au@Pd nanozymes with peroxidase activity by depositing metallic Pd on Au nanoparticles (Au NPs) synthesized using a trisodium citrate reduction method and ascorbic acid reduction. The in vitro validation was conducted through a series of experiments, including ROS detection, flow cytometry, CCK-8 assay, DNA damage assessment, live/dead cell staining, Western blot (WB), and qPCR. Tumor treatment was performed via tail vein injection of the drug, followed by HE staining of the treated tissues and biochemical analysis of the blood.
Au@Pd nanozymes can effectively accumulate at the tumor site through the EPR effect and exert peroxidase-like activity, catalyzing the excess HO in the tumor microenvironment to produce ROS. This triggers apoptosis pathways and DNA damage, leading to the downregulation of the anti-apoptotic protein Bcl-2, upregulation of the pro-apoptotic protein Bax, and induction of apoptosis-related genes, demonstrating strong anti-tumor effects.
This study developed an efficient nanozyme-mediated catalytic therapy strategy targeting the tumor microenvironment for the treatment of breast cancer cells.
乳腺癌具有高发病率和死亡率,是全球重大健康负担。传统治疗方法——手术、化疗和放疗——广泛应用,但存在复发、转移和显著副作用等缺点,包括对健康组织的损伤。为了解决这些局限性,正在开发新的治疗策略。过氧化物酶(POD)可以催化肿瘤微环境中过量的 HO 生成活性氧物种(ROS),通过破坏氧化还原平衡和调节凋亡相关蛋白来诱导癌细胞凋亡。然而,天然酶面临稳定性差、成本高和对环境条件敏感等挑战,限制了其在乳腺癌治疗中的应用。纳米酶作为具有酶样活性的纳米材料,通过克服这些限制提供了一种有前途的替代方法。
本研究通过在使用柠檬酸三钠还原法和抗坏血酸还原法合成的 Au 纳米粒子(Au NPs)上沉积金属 Pd,成功制备了具有过氧化物酶活性的 Au@Pd 纳米酶。通过一系列实验进行了体外验证,包括 ROS 检测、流式细胞术、CCK-8 测定、DNA 损伤评估、活/死细胞染色、Western blot(WB)和 qPCR。通过尾静脉注射药物进行肿瘤治疗,然后对处理过的组织进行 HE 染色和血液生化分析。
Au@Pd 纳米酶可以通过 EPR 效应有效聚集在肿瘤部位,并发挥过氧化物酶样活性,催化肿瘤微环境中过量的 HO 生成 ROS。这触发了凋亡途径和 DNA 损伤,导致抗凋亡蛋白 Bcl-2 下调,促凋亡蛋白 Bax 上调,并诱导凋亡相关基因,表现出强烈的抗肿瘤作用。
本研究开发了一种针对肿瘤微环境的高效纳米酶介导催化治疗策略,用于治疗乳腺癌细胞。